21-23 August 2017

Boston, MA, USA

Transforming Discovery & Translational Fibrosis Research into Disease Modifying IPF Therapeutics

 The inaugural Idiopathic Pulmonary Fibrosis (IPF) Summit is the only event to focus solely on IPF.

This unique meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development.

Across 3 jam-packed days the brightest minds from the likes of Boehringer Ingelheim, Promedior, Fibrogen and many more will be sharing their insight and lessons learned to collectively enable the community to:

  • Effectively translate into the clinic by better recapitulating IPF through robust in vitro & vivo models
  • Define more meaningful preclinical endpoints to aid identification of novel targets and development of more effective IPF therapeutics
  • Validate non-invasive biomarker & diagnostic techniques for back translation and ultimately achieve greater clinical benefit

Join your peers in Boston to overcome the challenges that are preventing you from accelerating the development of your IPF candidate.

 

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!” AstraZeneca - Previous Hanson Wade Life Sciences event attendee

This  Summit is for:

  • Large Pharma
  • Biotech
  • Academics looking to
    network with industry
  • Preclinical model providers
  • CROs

register widget homepage